

## WEST Search History





DATE: Wednesday, May 05, 2004

Hide?	Set Name	Query	Hit Count
		<i>DB=PGPB,USPT,EPAB,DWPI,TDBD; THES=ASSIGNEE; PLUR=YES; OP=ADJ</i>	
<input type="checkbox"/>	L6	exendin\$ same ((pharmaceutic\$ or therapeutic\$) same (composition? or fomulat\$)) and (m-cresol or 3-methylphenol)	2
<input type="checkbox"/>	L5	exendin\$ same ((pharmaceutic\$ or therapeutic\$) same (composition? or fomulat\$)) and (buffer? and (iso\$osmola\$ or isotonic\$)) and (preservative? or m-cresol or 3-methylphenol)	4
<input type="checkbox"/>	L4	exendin\$ same ((pharmaceutic\$ or therapeutic\$) same (composition? or fomulat\$)) and (buffer? and (iso\$osmola\$ or isotonic\$)) and (preservative? or \$cresol)	4
<input type="checkbox"/>	L3	exendin\$ same ((pharmaceutic\$ or therapeutic\$) same (composition? or fomulat\$)) and (buffer? and (iso\$osmola\$ or isotonic\$)) and (non-ion\$ same detergent? or surfactant?)	1
<input type="checkbox"/>	L2	exendin\$ same ((pharmaceutic\$ or therapeutic\$) same (composition? or fomulat\$)) and (buffer? and (iso\$osmola\$ or isotonic\$))	10
<input type="checkbox"/>	L1	(pharmaceutic\$ or therapeutic\$) same (composition? or fomulat\$) same exendin\$ same (buffer? and (iso\$osmola\$ or isotonic\$))	2

END OF SEARCH HISTORY

## Hit List

[Clear](#)[Generate Collection](#)[Print](#)[Fwd Refs](#)[Bkwd Refs](#)[Generate OACS](#)

Search Results - Record(s) 1 through 2 of 2 returned.

☐ 1. Document ID: US 20030087820 A1

Using default format because multiple data bases are involved.

L6: Entry 1 of 2

File: PGPB

May 8, 2003

PGPUB-DOCUMENT-NUMBER: 20030087820

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030087820 A1

TITLE: Novel exendin agonist formulations and methods of administration thereof

PUBLICATION-DATE: May 8, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Young, Andrew A.	La Jolla	CA	US	
Kolterman, Orville G.	Poway	CA	US	

US-CL-CURRENT: 514/12

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	R000	Draw Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	-----------	-------

☐ 2. Document ID: US 20030036504 A1

L6: Entry 2 of 2

File: PGPB

Feb 20, 2003

PGPUB-DOCUMENT-NUMBER: 20030036504

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030036504 A1

TITLE: Use of exendins and agonists thereof for modulation of triglyceride levels and treatment of dyslipidemia

PUBLICATION-DATE: February 20, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Kolterman, Orville G.	Poway	CA	US	
Young, Andrew A.	Point Loma	CA	US	

US-CL-CURRENT: 514/12

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMOC	Draw Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	-----------	-------

Clear	Generate Collection	Print	Fwd Refs	Bkwd Refs	Generate OACS
-------	---------------------	-------	----------	-----------	---------------

Term	Documents
M-CRESOL	8692
M-CRESOLS	44
3-METHYLPHENOL	365
3-METHYLPHENOLS	2
EXENDIN\$	0
EXENDIN	284
EXENDINE	2
EXENDINES	1
EXENDING	612
EXENDING-4	1
EXENDINS	45
(EXENDIN\$ SAME ((PHARMACEUTICS OR THERAPEUTICS) SAME (COMPOSITION? OR FOMULAT\$)) AND (M-CRESOL OR 3-METHYLPHENOL)).PGPB,USPT,EPAB,DWPI,TDBD.	2

There are more results than shown above. [Click here to view the entire set.](#)

Display Format:  [Change Format](#)

[Previous Page](#)

[Next Page](#)

[Go to Doc#](#)

## Hit List

Clear

Generate Collection

Print

Fwd Refs

Bkwd Refs

Generate OACS

Search Results - Record(s) 1 through 4 of 4 returned.

☐ 1. Document ID: US 20030087820 A1

Using default format because multiple data bases are involved.

L4: Entry 1 of 4

File: PGPB

May 8, 2003

PGPUB-DOCUMENT-NUMBER: 20030087820

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030087820 A1

TITLE: Novel exendin agonist formulations and methods of administration thereof

PUBLICATION-DATE: May 8, 2003

## INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Young, Andrew A.	La Jolla	CA	US	
Kolterman, Orville G.	Poway	CA	US	

US-CL-CURRENT: 514/12

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	RIMC	Draw Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	-----------	-------

☐ 2. Document ID: US 20030036504 A1

L4: Entry 2 of 4

File: PGPB

Feb 20, 2003

PGPUB-DOCUMENT-NUMBER: 20030036504

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030036504 A1

TITLE: Use of exendins and agonists thereof for modulation of triglyceride levels and treatment of dyslipidemia

PUBLICATION-DATE: February 20, 2003

## INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Kolterman, Orville G.	Poway	CA	US	
Young, Andrew A.	Point Loma	CA	US	

US-CL-CURRENT: 514/12

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWMC	Draw Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	-----------	-------

☐ 3. Document ID: US 6602694 B1

L4: Entry 3 of 4

File: USPT

Aug 5, 2003

US-PAT-NO: 6602694

DOCUMENT-IDENTIFIER: US 6602694 B1

TITLE: Uncoupling protein 4 (UCP-4)

DATE-ISSUED: August 5, 2003

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Albrandt; Keith	San Diego	CA		
Beaumont; Kevin	San Diego	CA		
Young; Andrew A.	San Diego	CA		

US-CL-CURRENT: 435/183; 530/333, 530/350

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWMC	Draw Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	-----------	-------

☐ 4. Document ID: US 6528486 B1

L4: Entry 4 of 4

File: USPT

Mar 4, 2003

US-PAT-NO: 6528486

DOCUMENT-IDENTIFIER: US 6528486 B1

TITLE: Peptide agonists of GLP-1 activity

DATE-ISSUED: March 4, 2003

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Larsen; Bjarne Due	Br.o slashed.nsh.o slashed.j			DK
Mikkelsen; Jens Damsgaard	Lyngby			DK
Neve; S.o slashed.ren	Lyngby			DK

US-CL-CURRENT: 514/12; 514/2, 530/300, 530/303

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWMC	Draw Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	-----------	-------

Clear

Generate Collection

Print

Fwd Refs

Bkwd Refs

Generate OACS

Term

Documents

EXENDINS	0
EXENDIN	286
EXENDINE	2
EXENDINES	1
EXENDING	612
EXENDING-4	1
EXENDINS	45
EXENDIN4	11
EXENDIN-AGONIST	1
EXENDIN-ANALOGS	1
EXENDIN-ENCODING	1
(EXENDINS SAME ((PHARMACEUTICS OR THERAPEUTICS) SAME (COMPOSITION? OR FOMULAT\$)) AND (BUFFER? AND (ISO\$OSMOLA\$ OR ISOTONIC\$)) AND (PRESERVATIVE? OR \$CRESOL)).PGPB,USPT,EPAB,DWPI,TDBD.	4

There are more results than shown above. [Click here to view the entire set.](#)

Display Format:  [Change Format](#)

[Previous Page](#)

[Next Page](#)

[Go to Doc#](#)

## Hit List

Clear

Generate Collection

Print

Fwd Refs

Bkwd Refs

Generate OACS

Search Results - Record(s) 1 through 1 of 1 returned.

☐ 1. Document ID: US 6528486 B1

Using default format because multiple data bases are involved.

L3: Entry 1 of 1

File: USPT

Mar 4, 2003

US-PAT-NO: 6528486

DOCUMENT-IDENTIFIER: US 6528486 B1

TITLE: Peptide agonists of GLP-1 activity

DATE-ISSUED: March 4, 2003

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Larsen; Bjarne Due	Br.o slashed.nsh.o slashed.j			DK
Mikkelsen; Jens Damsgaard	Lyngby			DK
Neve; S.o slashed.ren	Lyngby			DK

US-CL-CURRENT: 514/12; 514/2, 530/300, 530/303

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	RMC	Draw Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	-----	-----------	-------

Clear

Generate Collection

Print

Fwd Refs

Bkwd Refs

Generate OACS

Term	Documents
EXENDIN\$	0
EXENDIN	286
EXENDINE	2
EXENDINES	1
EXENDING	612
EXENDING-4	1
EXENDINS	45
EXENDIN4	11
EXENDIN-AGONIST	1
EXENDIN-ANALOGS	1
EXENDIN-ENCODING	1
(EXENDIN\$ SAME ((PHARMACEUTIC\$ OR THERAPEUTIC\$) SAME	

(COMPOSITION? OR FOMULAT\$)) AND (BUFFER? AND (ISO\$OSMOLAS\$ OR ISOTONICS\$)) AND (NON-ION\$ SAME DETERGENT? OR SURFACTANT?)).PGPB,USPT,EPAB,DWPI,TDBD.	1
--	---

There are more results than shown above. [Click here to view the entire set.](#)

Display Format:  [Change Format](#)

[Previous Page](#)   [Next Page](#)   [Go to Doc#](#)



## Hit List

Clear

Generate Collection

Print

Fwd Refs

Bkwd Refs

Generate OACS

Search Results - Record(s) 1 through 10 of 10 returned.

☐ 1. Document ID: US 20040023871 A1

Using default format because multiple data bases are involved.

L2: Entry 1 of 10

File: PGPB

Feb 5, 2004

PGPUB-DOCUMENT-NUMBER: 20040023871

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040023871 A1

TITLE: Use of exendins and agonists thereof for the treatment of gestational diabetes mellitus

PUBLICATION-DATE: February 5, 2004

## INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Hiles, Richard A.	San Diego	CA	US	
Prickett, Kathryn S.	San Diego	CA	US	

US-CL-CURRENT: 514/12

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	RMIC	Draw Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	-----------	-------

☐ 2. Document ID: US 20030087821 A1

L2: Entry 2 of 10

File: PGPB

May 8, 2003

PGPUB-DOCUMENT-NUMBER: 20030087821

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030087821 A1

TITLE: Exendins, exendin agonists, and methods for their use

PUBLICATION-DATE: May 8, 2003

## INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Beeley, Nigel Robert Arnold	Solana Beach	CA	US	
Prickett, Kathryn S.	San Diego	CA	US	
Bhavsar, Sunil	San Diego	CA	US	

US-CL-CURRENT: 514/12

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	-----------	-------

☐ 3. Document ID: US 20030087820 A1

L2: Entry 3 of 10

File: PGPB

May 8, 2003

PGPUB-DOCUMENT-NUMBER: 20030087820

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030087820 A1

TITLE: Novel exendin agonist formulations and methods of administration thereof

PUBLICATION-DATE: May 8, 2003

## INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Young, Andrew A.	La Jolla	CA	US	
Kolterman, Orville G.	Poway	CA	US	

US-CL-CURRENT: 514/12

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	-----------	-------

☐ 4. Document ID: US 20030036504 A1

L2: Entry 4 of 10

File: PGPB

Feb 20, 2003

PGPUB-DOCUMENT-NUMBER: 20030036504

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030036504 A1

TITLE: Use of exendins and agonists thereof for modulation of triglyceride levels and treatment of dyslipidemia

PUBLICATION-DATE: February 20, 2003

## INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Kolterman, Orville G.	Poway	CA	US	
Young, Andrew A.	Point Loma	CA	US	

US-CL-CURRENT: 514/12

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	-----------	-------

☐ 5. Document ID: US 20020141985 A1

L2: Entry 5 of 10

File: PGPB

Oct 3, 2002

PGPUB-DOCUMENT-NUMBER: 20020141985  
PGPUB-FILING-TYPE: new  
DOCUMENT-IDENTIFIER: US 20020141985 A1

TITLE: Peptide YY and peptide YY agonists for treatment of metabolic disorders

PUBLICATION-DATE: October 3, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Pittner, Richard A.	San Diego	CA	US	
Young, Andrew A.	La Jolla	CA	US	
Paterniti, James R. JR.	San Diego	CA	US	

US-CL-CURRENT: 424/94.1

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWC	Draw Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	-----------	-------

☐ 6. Document ID: US 20020137666 A1

L2: Entry 6 of 10

File: PGPB

Sep 26, 2002

PGPUB-DOCUMENT-NUMBER: 20020137666  
PGPUB-FILING-TYPE: new  
DOCUMENT-IDENTIFIER: US 20020137666 A1

TITLE: USE OF EXENDINS AND AGONISTS THEREOF FOR THE REDUCTION OF FOOD INTAKE

PUBLICATION-DATE: September 26, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
BEELEY, NIGEL ROBERT ARNOLD	SOLANA BEACH	CA	US	
PRICKETT, KATHRYN S.	SAN DIEGO	CA	US	
BHAVSAR, SUNIL	SAN DIEGO	CA	US	

US-CL-CURRENT: 514/2; 514/12, 530/350

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWC	Draw Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	-----------	-------

☐ 7. Document ID: US 6703359 B1

L2: Entry 7 of 10

File: USPT

Mar 9, 2004

US-PAT-NO: 6703359  
DOCUMENT-IDENTIFIER: US 6703359 B1

TITLE: Inotropic and diuretic effects of exendin and GLP-1

DATE-ISSUED: March 9, 2004

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Young; Andrew A.	San Diego	CA		
Vine; Will	Poway	CA		
Beeley; Nigel R. A.	Solana Beach	CA		
Prickett; Kathryn	San Diego	CA		

US-CL-CURRENT: 514/2; 514/866, 530/324

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	FIGS	Draw Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-----------	-------

☐ 8. Document ID: US 6602694 B1

L2: Entry 8 of 10

File: USPT

Aug 5, 2003

US-PAT-NO: 6602694

DOCUMENT-IDENTIFIER: US 6602694 B1

TITLE: Uncoupling protein 4 (UCP-4)

DATE-ISSUED: August 5, 2003

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Albrandt; Keith	San Diego	CA		
Beaumont; Kevin	San Diego	CA		
Young; Andrew A.	San Diego	CA		

US-CL-CURRENT: 435/183; 530/333, 530/350

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	FIGS	Draw Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-----------	-------

☐ 9. Document ID: US 6528486 B1

L2: Entry 9 of 10

File: USPT

Mar 4, 2003

US-PAT-NO: 6528486

DOCUMENT-IDENTIFIER: US 6528486 B1

TITLE: Peptide agonists of GLP-1 activity

DATE-ISSUED: March 4, 2003

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Larsen; Bjarne Due	Br.o slashed.nsh.o slashed.j			DK
Mikkelsen; Jens Damsgaard	Lyngby			DK
Neve; S.o slashed.ren	Lyngby			DK

US-CL-CURRENT: 514/12; 514/2, 530/300, 530/303

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	PubC	Draw Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-----------	-------

☐ 10. Document ID: US 6506724 B1

L2: Entry 10 of 10

File: USPT

Jan 14, 2003

US-PAT-NO: 6506724

DOCUMENT-IDENTIFIER: US 6506724 B1

TITLE: Use of exendins and agonists thereof for the treatment of gestational diabetes mellitus

DATE-ISSUED: January 14, 2003

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Hiles; Richard A.	San Diego	CA		
Prickett; Kathryn S.	San Diego	CA		

US-CL-CURRENT: 514/2; 514/12, 514/3, 514/4, 514/866, 530/300, 530/324, 530/325

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	PubC	Draw Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-----------	-------

Clear

Generate Collection

Print

Fwd Refs

Bkwd Refs

Generate OACS

Term	Documents
EXENDIN\$	0
EXENDIN	286
EXENDINE	2
EXENDINES	1
EXENDING	612
EXENDING-4	1
EXENDINS	45
EXENDIN4	11
EXENDIN-AGONIST	1
EXENDIN-ANALOGS	1
EXENDIN-ENCODING	1
(EXENDIN\$ SAME ((PHARMACEUTICS\$ OR THERAPEUTICS\$) SAME (COMPOSITION? OR FOMULATS)) AND (BUFFER? AND (ISOSOSMOLAS\$ OR ISOTONICS))).PGPB,USPT,EPAB,DWPI,TDBD.	10

There are more results than shown above. [Click here to view the entire set.](#)

**Display Format:**  [Change Format](#)

[Previous Page](#)

[Next Page](#)

[Go to Doc#](#)

FILE 'HOME' ENTERED AT 12:18:31 ON 05 MAY 2004

=> file bioscience medicine

FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED  
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.21	0.21

FULL ESTIMATED COST

FILE 'ADISCTI' ENTERED AT 12:19:18 ON 05 MAY 2004  
COPYRIGHT (C) 2004 Adis Data Information BV

FILE 'ADISINSIGHT' ENTERED AT 12:19:18 ON 05 MAY 2004  
COPYRIGHT (C) 2004 Adis Data Information BV

FILE 'ADISNEWS' ENTERED AT 12:19:18 ON 05 MAY 2004  
COPYRIGHT (C) 2004 Adis Data Information BV

FILE 'AGRICOLA' ENTERED AT 12:19:18 ON 05 MAY 2004

FILE 'ANABSTR' ENTERED AT 12:19:18 ON 05 MAY 2004  
COPYRIGHT (c) 2004 THE ROYAL SOCIETY OF CHEMISTRY (RSC)

FILE 'AQUASCI' ENTERED AT 12:19:18 ON 05 MAY 2004  
COPYRIGHT 2004 FAO (On behalf of the ASFA Advisory Board). All rights reserved.

FILE 'BIOBUSINESS' ENTERED AT 12:19:18 ON 05 MAY 2004  
COPYRIGHT (C) 2004 Biological Abstracts, Inc. (BIOSIS)

FILE 'BIOCOMMERCE' ENTERED AT 12:19:18 ON 05 MAY 2004  
COPYRIGHT (C) 2004 BioCommerce Data Ltd. Richmond Surrey, United Kingdom. All rights reserved

FILE 'BIOSIS' ENTERED AT 12:19:18 ON 05 MAY 2004  
COPYRIGHT (C) 2004 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'BIOTECHABS' ACCESS NOT AUTHORIZED

FILE 'BIOTECHDS' ENTERED AT 12:19:18 ON 05 MAY 2004  
COPYRIGHT (C) 2004 THOMSON DERWENT AND INSTITUTE FOR SCIENTIFIC INFORMATION

FILE 'BIOTECHNO' ENTERED AT 12:19:18 ON 05 MAY 2004  
COPYRIGHT (C) 2004 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'CABA' ENTERED AT 12:19:18 ON 05 MAY 2004  
COPYRIGHT (C) 2004 CAB INTERNATIONAL (CABI)

FILE 'CANCERLIT' ENTERED AT 12:19:18 ON 05 MAY 2004

FILE 'CAPLUS' ENTERED AT 12:19:18 ON 05 MAY 2004  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'CEABA-VTB' ENTERED AT 12:19:18 ON 05 MAY 2004  
COPYRIGHT (c) 2004 DECHEMA eV

FILE 'CEN' ENTERED AT 12:19:18 ON 05 MAY 2004  
COPYRIGHT (C) 2004 American Chemical Society (ACS)

FILE 'CIN' ENTERED AT 12:19:18 ON 05 MAY 2004  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2004 American Chemical Society (ACS)

FILE 'CONFSCI' ENTERED AT 12:19:18 ON 05 MAY 2004  
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'CROPB' ENTERED AT 12:19:18 ON 05 MAY 2004  
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'CROPU' ENTERED AT 12:19:18 ON 05 MAY 2004  
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'DISSABS' ENTERED AT 12:19:18 ON 05 MAY 2004  
COPYRIGHT (C) 2004 ProQuest Information and Learning Company; All Rights Reserved.

FILE 'DDFB' ACCESS NOT AUTHORIZED

FILE 'DDFU' ACCESS NOT AUTHORIZED

FILE 'DGENE' ENTERED AT 12:19:18 ON 05 MAY 2004  
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'DRUGB' ENTERED AT 12:19:18 ON 05 MAY 2004  
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'DRUGMONOG2' ENTERED AT 12:19:18 ON 05 MAY 2004  
COPYRIGHT (C) 2004 IMSWORLD Publications Ltd

FILE 'IMSDRUGNEWS' ENTERED AT 12:19:18 ON 05 MAY 2004  
COPYRIGHT (C) 2004 IMSWORLD Publications Ltd

FILE 'DRUGU' ENTERED AT 12:19:18 ON 05 MAY 2004  
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'IMSRESEARCH' ENTERED AT 12:19:18 ON 05 MAY 2004  
COPYRIGHT (C) 2004 IMSWORLD Publications Ltd

FILE 'EMBAL' ENTERED AT 12:19:18 ON 05 MAY 2004  
COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'EMBASE' ENTERED AT 12:19:18 ON 05 MAY 2004  
COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'ESBIOBASE' ENTERED AT 12:19:18 ON 05 MAY 2004  
COPYRIGHT (C) 2004 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'FEDRIP' ENTERED AT 12:19:18 ON 05 MAY 2004

FILE 'FOMAD' ENTERED AT 12:19:18 ON 05 MAY 2004  
COPYRIGHT (C) 2004 Leatherhead Food Research Association

FILE 'FOREGE' ENTERED AT 12:19:18 ON 05 MAY 2004  
COPYRIGHT (C) 2004 Leatherhead Food Research Association

FILE 'FROSTI' ENTERED AT 12:19:18 ON 05 MAY 2004  
COPYRIGHT (C) 2004 Leatherhead Food Research Association

FILE 'FSTA' ENTERED AT 12:19:18 ON 05 MAY 2004  
COPYRIGHT (C) 2004 International Food Information Service

FILE 'GENBANK' ENTERED AT 12:19:18 ON 05 MAY 2004

FILE 'HEALSAFE' ENTERED AT 12:19:18 ON 05 MAY 2004  
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'IFIPAT' ENTERED AT 12:19:18 ON 05 MAY 2004  
COPYRIGHT (C) 2004 IFI CLAIMS(R) Patent Services (IFI)

FILE 'IMSPRODUCT' ENTERED AT 12:19:18 ON 05 MAY 2004  
COPYRIGHT (C) 2004 IMSWORLD Publications Ltd



FILE 'JICST-EPLUS' ENTERED AT 12:19:18 ON 05 MAY 2004  
COPYRIGHT (C) 2004 Japan Science and Technology Agency (JST)

FILE 'KOSMET' ENTERED AT 12:19:18 ON 05 MAY 2004  
COPYRIGHT (C) 2004 International Federation of the Societies of Cosmetics Chemists

FILE 'LIFESCI' ENTERED AT 12:19:18 ON 05 MAY 2004  
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'MEDICONF' ENTERED AT 12:19:18 ON 05 MAY 2004  
COPYRIGHT (c) 2004 FAIRBASE Datenbank GmbH, Hannover, Germany

FILE 'MEDLINE' ENTERED AT 12:19:18 ON 05 MAY 2004

FILE 'NIOSHTIC' ENTERED AT 12:19:18 ON 05 MAY 2004  
COPYRIGHT (C) 2004 U.S. Secretary of Commerce on Behalf of the U.S. Government

FILE 'NTIS' ENTERED AT 12:19:18 ON 05 MAY 2004  
Compiled and distributed by the NTIS, U.S. Department of Commerce.  
It contains copyrighted material.  
All rights reserved. (2004)

FILE 'NUTRACEUT' ENTERED AT 12:19:18 ON 05 MAY 2004  
Copyright 2004 (c) MARKETLETTER Publications Ltd. All rights reserved.

FILE 'OCEAN' ENTERED AT 12:19:18 ON 05 MAY 2004  
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'PASCAL' ENTERED AT 12:19:18 ON 05 MAY 2004  
Any reproduction or dissemination in part or in full,  
by means of any process and on any support whatsoever  
is prohibited without the prior written agreement of INIST-CNRS.  
COPYRIGHT (C) 2004 INIST-CNRS. All rights reserved.

FILE 'PCTGEN' ENTERED AT 12:19:18 ON 05 MAY 2004  
COPYRIGHT (C) 2004 WIPO

FILE 'PHAR' ENTERED AT 12:19:18 ON 05 MAY 2004  
COPYRIGHT (C) 2004 PJB Publications Ltd. (PJB)

FILE 'PHARMAML' ENTERED AT 12:19:18 ON 05 MAY 2004  
Copyright 2004 (c) MARKETLETTER Publications Ltd. All rights reserved.

FILE 'PHIC' ENTERED AT 12:19:18 ON 05 MAY 2004  
COPYRIGHT (C) 2004 PJB Publications Ltd. (PJB)

FILE 'PHIN' ENTERED AT 12:19:18 ON 05 MAY 2004  
COPYRIGHT (C) 2004 PJB Publications Ltd. (PJB)

FILE 'PROMT' ENTERED AT 12:19:18 ON 05 MAY 2004  
COPYRIGHT (C) 2004 Gale Group. All rights reserved.

FILE 'RDISCLOSURE' ENTERED AT 12:19:18 ON 05 MAY 2004  
COPYRIGHT (C) 2004 Kenneth Mason Publications Ltd.

FILE 'SCISEARCH' ENTERED AT 12:19:18 ON 05 MAY 2004  
COPYRIGHT 2004 THOMSON ISI

FILE 'SYNTHLINE' ENTERED AT 12:19:18 ON 05 MAY 2004  
COPYRIGHT (C) 2004 Prous Science

FILE 'TOXCENTER' ENTERED AT 12:19:18 ON 05 MAY 2004  
COPYRIGHT (C) 2004 ACS

FILE 'USPATFULL' ENTERED AT 12:19:18 ON 05 MAY 2004  
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 12:19:18 ON 05 MAY 2004  
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'VETB' ENTERED AT 12:19:18 ON 05 MAY 2004  
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'VETU' ENTERED AT 12:19:18 ON 05 MAY 2004  
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'WPIDS' ENTERED AT 12:19:18 ON 05 MAY 2004  
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'WPIFV' ENTERED AT 12:19:18 ON 05 MAY 2004  
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'WPINDEX' ACCESS NOT AUTHORIZED

FILE 'IPA' ENTERED AT 12:19:18 ON 05 MAY 2004  
COPYRIGHT (C) 2004 American Society of Hospital Pharmacists (ASHP)

FILE 'NAPRALERT' ENTERED AT 12:19:18 ON 05 MAY 2004  
COPYRIGHT (C) 2004 Board of Trustees of the University of Illinois,  
University of Illinois at Chicago.

FILE 'NLDB' ENTERED AT 12:19:18 ON 05 MAY 2004  
COPYRIGHT (C) 2004 Gale Group. All rights reserved.

=> s exendin? (s)((pharmaceutic? or therapeutic?) (s) (composition# or fomulat?)) and  
(buffer and (iso?osmola? or isotonic?)) and (preservative or m-cresol or 3 (w)  
methylphenol)

'?' TRUNCATION SYMBOL NOT VALID WITHIN 'ISO?OSMOLA?'

The truncation symbol ? may be used only at the end of a search  
term. To specify a variable character within a word use '!', e.g.,  
'wom!n' to search for both 'woman' and 'women'. Enter "HELP  
TRUNCATION" at an arrow prompt (=>) for more information.

=> s exendin? (s)((pharmaceutic? or therapeutic?) (s) (composition# or fomulat?)) and  
(buffer and (?osmola? or isotonic?))and (preservative or m-cresol or 3 (w) methylphenol)  
LEFT TRUNCATION IGNORED FOR '?OSMOLA?' FOR FILE 'ADISCTI'

L1 0 FILE ADISCTI

LEFT TRUNCATION IGNORED FOR '?OSMOLA?' FOR FILE 'ADISINSIGHT'

L2 0 FILE ADISINSIGHT

LEFT TRUNCATION IGNORED FOR '?OSMOLA?' FOR FILE 'ADISNEWS'

L3 0 FILE ADISNEWS

LEFT TRUNCATION IGNORED FOR '?OSMOLA?' FOR FILE 'AGRICOLA'

L4 0 FILE AGRICOLA

L5 0 FILE ANABSTR

LEFT TRUNCATION IGNORED FOR '?OSMOLA?' FOR FILE 'AQUASCI'

L6 0 FILE AQUASCI

LEFT TRUNCATION IGNORED FOR '?OSMOLA?' FOR FILE 'BIOBUSINESS'

L7 0 FILE BIOBUSINESS

LEFT TRUNCATION IGNORED FOR '?OSMOLA?' FOR FILE 'BIOCOMMERCE'

L8 0 FILE BIOCOMMERCE

L9 0 FILE BIOSIS

LEFT TRUNCATION IGNORED FOR '?OSMOLA?' FOR FILE 'BIOTECHDS'

L10 0 FILE BIOTECHDS

L11 0 FILE BIOTECHNO

L12 0 FILE CABA

L13 0 FILE CANCERLIT

L14 0 FILE CAPLUS

LEFT TRUNCATION IGNORED FOR '?OSMOLA?' FOR FILE 'CEABA-VTB'

L15 0 FILE CEABA-VTB

LEFT TRUNCATION IGNORED FOR '?OSMOLA?' FOR FILE 'CEN'  
L16 0 FILE CEN  
L17 0 FILE CIN  
LEFT TRUNCATION IGNORED FOR '?OSMOLA?' FOR FILE 'CONFSCI'  
L18 0 FILE CONFSCI  
LEFT TRUNCATION IGNORED FOR '?OSMOLA?' FOR FILE 'CROPB'  
L19 0 FILE CROPB  
LEFT TRUNCATION IGNORED FOR '?OSMOLA?' FOR FILE 'CROPU'  
L20 0 FILE CROPU  
L21 0 FILE DISSABS  
LEFT TRUNCATION IGNORED FOR '?OSMOLA?' FOR FILE 'DGENE'  
L22 0 FILE DGENE  
LEFT TRUNCATION IGNORED FOR '?OSMOLA?' FOR FILE 'DRUGB'  
L23 0 FILE DRUGB  
LEFT TRUNCATION IGNORED FOR '?OSMOLA?' FOR FILE 'DRUGMONOG2'  
L24 0 FILE DRUGMONOG2  
LEFT TRUNCATION IGNORED FOR '?OSMOLA?' FOR FILE 'IMSDRUGNEWS'  
L25 0 FILE IMSDRUGNEWS  
LEFT TRUNCATION IGNORED FOR '?OSMOLA?' FOR FILE 'DRUGU'  
L26 0 FILE DRUGU  
LEFT TRUNCATION IGNORED FOR '?OSMOLA?' FOR FILE 'IMSRESEARCH'  
L27 0 FILE IMSRESEARCH  
LEFT TRUNCATION IGNORED FOR '?OSMOLA?' FOR FILE 'EMBAL'  
L28 0 FILE EMBAL  
L29 0 FILE EMBASE  
LEFT TRUNCATION IGNORED FOR '?OSMOLA?' FOR FILE 'ESBIOBASE'  
L30 0 FILE ESBIOBASE  
LEFT TRUNCATION IGNORED FOR '?OSMOLA?' FOR FILE 'FEDRIP'  
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH  
FIELD CODE - 'AND' OPERATOR ASSUMED 'APEUTIC?) (S) '  
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH  
FIELD CODE - 'AND' OPERATOR ASSUMED 'EXENDIN? (S) ('  
L31 0 FILE FEDRIP  
LEFT TRUNCATION IGNORED FOR '?OSMOLA?' FOR FILE 'FOMAD'  
L32 0 FILE FOMAD  
LEFT TRUNCATION IGNORED FOR '?OSMOLA?' FOR FILE 'FOREGE'  
L33 0 FILE FOREGE  
L34 0 FILE FROSTI  
L35 0 FILE FSTA  
L36 0 FILE GENBANK  
LEFT TRUNCATION IGNORED FOR '?OSMOLA?' FOR FILE 'HEALSAFE'  
L37 0 FILE HEALSAFE  
L38 0 FILE IFIPAT  
LEFT TRUNCATION IGNORED FOR '?OSMOLA?' FOR FILE 'IMSPRODUCT'  
L39 0 FILE IMSPRODUCT  
LEFT TRUNCATION IGNORED FOR '?OSMOLA?' FOR FILE 'JICST-EPLUS'  
L40 0 FILE JICST-EPLUS  
L41 0 FILE KOSMET  
LEFT TRUNCATION IGNORED FOR '?OSMOLA?' FOR FILE 'LIFESCI'  
L42 0 FILE LIFESCI  
L43 0 FILE MEDICONF  
L44 0 FILE MEDLINE  
LEFT TRUNCATION IGNORED FOR '?OSMOLA?' FOR FILE 'NIOSHTIC'  
L45 0 FILE NIOSHTIC  
L46 0 FILE NTIS  
LEFT TRUNCATION IGNORED FOR '?OSMOLA?' FOR FILE 'NUTRACEUT'  
L47 0 FILE NUTRACEUT  
LEFT TRUNCATION IGNORED FOR '?OSMOLA?' FOR FILE 'OCEAN'  
L48 0 FILE OCEAN  
L49 0 FILE PASCAL  
LEFT TRUNCATION IGNORED FOR '?OSMOLA?' FOR FILE 'PCTGEN'  
L50 0 FILE PCTGEN  
L51 0 FILE PHAR  
LEFT TRUNCATION IGNORED FOR '?OSMOLA?' FOR FILE 'PHARMAML'  
L52 0 FILE PHARMAML  
L53 0 FILE PHIC

L54 0 FILE PHIN  
 LEFT TRUNCATION IGNORED FOR '?OSMOLA?' FOR FILE 'PROMT'  
 L55 0 FILE PROMT  
 L56 0 FILE RDISCLOSURE  
 L57 0 FILE SCISEARCH  
 LEFT TRUNCATION IGNORED FOR '?OSMOLA?' FOR FILE 'SYNTHLINE'  
 L58 0 FILE SYNTHLINE  
 L59 0 FILE TOXCENTER  
 L60 5 FILE USPATFULL  
 L61 0 FILE USPAT2  
 LEFT TRUNCATION IGNORED FOR '?OSMOLA?' FOR FILE 'VETB'  
 L62 0 FILE VETB  
 LEFT TRUNCATION IGNORED FOR '?OSMOLA?' FOR FILE 'VETU'  
 L63 0 FILE VETU  
 L64 3 FILE WPIDS  
 L65 0 FILE WPIFV  
 LEFT TRUNCATION IGNORED FOR '?OSMOLA?' FOR FILE 'IPA'  
 L66 0 FILE IPA  
 L67 0 FILE NAPRALERT  
 LEFT TRUNCATION IGNORED FOR '?OSMOLA?' FOR FILE 'NLDB'  
 L68 0 FILE NLDB

TOTAL FOR ALL FILES

L69 8 EXENDIN? (S)((PHARMACEUTIC? OR THERAPEUTIC?) (S) (COMPOSITION#  
 OR FOMULAT?)) AND (BUFFER AND (?OSMOLA? OR ISOTONIC?)) AND (PRES  
 ERVATIVE OR M-CRESOL OR 3 (W) METHYLPHENOL)

Left truncation is not valid in the specified search field in the  
 specified file. The term has been searched without left truncation.  
 Examples: '?TERPEN?' would be searched as 'TERPEN?' and '?FLAVONOID'  
 would be searched as 'FLAVONOID.'

If you are searching in a field that uses implied proximity, and you  
 used a truncation symbol after a punctuation mark, the system may  
 interpret the truncation symbol as being at the beginning of a term.  
 Implied proximity is used in search fields indexed as single words,  
 for example, the Basic Index.

=> d 169 1-8 ibib abs

L69 ANSWER 1 OF 8 USPATFULL on STN

ACCESSION NUMBER: 2003:209956 USPATFULL  
 TITLE: Uncoupling protein 4 (UCP-4)  
 INVENTOR(S): Albrandt, Keith, San Diego, CA, United States  
 Beaumont, Kevin, San Diego, CA, United States  
 Young, Andrew A., San Diego, CA, United States  
 PATENT ASSIGNEE(S): Amylin Pharmaceuticals, Inc, San Diego, CA, United  
 States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6602694	B1	20030805
	WO 2000004037		20000127
APPLICATION INFO.:	US 2001-743847		20010627 (9)
	WO 1999-US15861		19990713

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-92737P	19980714 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Eyler, Yvonne	
ASSISTANT EXAMINER:	Li, Ruixiang	
NUMBER OF CLAIMS:	5	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	5 Drawing Figure(s); 5 Drawing Page(s)	
LINE COUNT:	2275	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A novel uncoupling protein, which we have designated UCP-4, that is expressed in various tissues, including brain, heart, pancreas, and muscle tissue, and nucleic acid molecules which encode for said novel protein, are described. Methods of screening for compounds that regulate the expression and the activity of UCP-4 are described, as well as methods of treating diseases or conditions in which the regulation of thermogenesis or respiratory ATP synthesis is desired. Such conditions include obesity, diabetes, malignant hyperthermia, and fever. The construction of cell lines that express UCP-4 is also described.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L69 ANSWER 2 OF 8 USPATFULL on STN

ACCESSION NUMBER: 2003:127605 USPATFULL

TITLE: Novel exendin agonist formulations and methods of administration thereof

INVENTOR(S): Young, Andrew A., La Jolla, CA, UNITED STATES  
Kolterman, Orville G., Poway, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003087820	A1	20030508
APPLICATION INFO.:	US 2002-157224	A1	20020528 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2001-889330, filed on 27 Dec 2001, PENDING A 371 of International Ser. No. WO 2000-US902, filed on 14 Jan 2000, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-116380P	19990114 (60)
	US 2000-175365P	20000110 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Molly A. Holman, Ph.D., Amylin Pharmaceuticals, Inc., 9373 Towne Centre Drive, San Diego, CA, 92121	
NUMBER OF CLAIMS:	40	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	25 Drawing Page(s)	
LINE COUNT:	3512	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Novel exendin and exendin agonist compound formulations and dosages and methods of administration thereof are provided. These compositions and methods are useful in treating diabetes and conditions that would be benefited by lowering plasma glucose or delaying and/or slowing gastric emptying or inhibiting food intake.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L69 ANSWER 3 OF 8 USPATFULL on STN

ACCESSION NUMBER: 2003:60207 USPATFULL

TITLE: Peptide agonists of GLP-1 activity

INVENTOR(S): Larsen, Bjarne Due, Br.o slashed.nsh.o slashed.j, DENMARK

Mikkelsen, Jens Damsgaard, Lyngby, DENMARK  
Neve, S.o slashed.ren, Lyngby, DENMARK

PATENT ASSIGNEE(S): Zealand Pharma A/S, Glostrup, DENMARK (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6528486	B1	20030304
APPLICATION INFO.:	US 2000-614847		20000712 (9)

NUMBER	DATE
--------	------

PRIORITY INFORMATION: US 1999-143591P 19990712 (60)  
DOCUMENT TYPE: Utility  
FILE SEGMENT: GRANTED  
PRIMARY EXAMINER: Spector, Lorraine  
ASSISTANT EXAMINER: Jiang, Dong  
LEGAL REPRESENTATIVE: Buchanan, Robert L., Edwards & Angell, LLP  
NUMBER OF CLAIMS: 2  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 8 Drawing Figure(s); 8 Drawing Page(s)  
LINE COUNT: 3573

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to novel peptide conjugates which have increased stability and are useful in the treatment of excess levels of blood glucose.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L69 ANSWER 4 OF 8 USPATFULL on STN

ACCESSION NUMBER: 2003:51546 USPATFULL  
TITLE: Use of exendins and agonists thereof for modulation of triglyceride levels and treatment of dyslipidemia  
INVENTOR(S): Kolterman, Orville G., Poway, CA, UNITED STATES  
Young, Andrew A., Point Loma, CA, UNITED STATES  
PATENT ASSIGNEE(S): Amylin Pharmaceuticals, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003036504	A1	20030220
APPLICATION INFO.:	US 2001-756690	A1	20010109 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-175365P	20000110 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	BROBECK, PHLEGER & HARRISON LLP, 12390 EL CAMINO REAL, SAN DIEGO, CA, 92130	
NUMBER OF CLAIMS:	40	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	5 Drawing Page(s)	
LINE COUNT:	5350	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods for modulating the levels of plasma triglyceride and other lipids in a subject which comprise administration of an effective amount of an exendin or an exendin agonist, alone or in conjunction with other compounds or compositions that lower blood triglyceride and/or other lipid levels.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L69 ANSWER 5 OF 8 USPATFULL on STN

ACCESSION NUMBER: 2001:218592 USPATFULL  
TITLE: Exendin derivatives  
INVENTOR(S): Knudsen, Liselotte Bjerre, Valby, Denmark  
Huusfeldt, Per Olaf, Copenhagen K, Denmark  
Nielsen, Per Franklin, Vaerloose, Denmark  
Madsen, Kjeld, Vaerloose, Denmark

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2001047084	A1	20011129
APPLICATION INFO.:	US 2001-886311	A1	20010621 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1999-312177, filed on 14 May 1999, ABANDONED Continuation of Ser. No. WO 1999-DK86, filed on 24 Feb 1999, UNKNOWN		

	NUMBER	DATE
PRIORITY INFORMATION:	DK 1998-274	19980227
	US 1998-84357P	19980505 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Reza Green, Esq., Novo Nordisk of North America, Inc., Suite 6400, 405 Lexington Avenue, New York, NY, 10174-6401	
NUMBER OF CLAIMS:	91	
EXEMPLARY CLAIM:	1	
LINE COUNT:	2488	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		
AB	The present invention relates to a derivative of GLP-1 (7-C), wherein C is 35 or 36 which derivative has just one lipophilic substituent which is attached to the C-terminal amino acid residue.	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L69 ANSWER 6 OF 8 WPIDS COPYRIGHT 2004 THOMSON DERWENT on STN

ACCESSION NUMBER:	2004-022543 [02]	WPIDS
DOC. NO. CPI:	C2004-007005	
TITLE:	Use of a glucagon like peptide-1 agonist or its salt for the preparation of a pharmaceutical composition for the treatment or prevention of an early cardiac or early cardiovascular disease in a diabetic or non-diabetic patient.	
DERWENT CLASS:	B04	
INVENTOR(S):	CARR, R D; CHRISTOFFERSEN, C; ELBROND, B; KNUDSEN, L B; LARSEN, J; NIELSEN, L B; ROLIN, B C; SELMER, J	
PATENT ASSIGNEE(S):	(CARR-I) CARR R D; (CHRI-I) CHRISTOFFERSEN C; (ELBR-I) ELBROND B; (KNUD-I) KNUDSEN L B; (LARS-I) LARSEN J; (NIEL-I) NIELSEN L B; (ROLI-I) ROLIN B C; (SELM-I) SELMER J; (NOVO) NOVO NORDISK AS	
COUNTRY COUNT:	103	
PATENT INFORMATION:		

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 2003084563	A1	20031016	(200402)*	EN	14
RW: AT BE BG CH CY CZ DE DK EA EE ES FI FR GB GH GM GR HU IE IT KE LS LU MC MW MZ NL OA PT RO SD SE SI SK SL SZ TR TZ UG ZM ZW					
W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW					
US 2003220255	A1	20031127	(200402)		

# APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2003084563	A1	WO 2003-DK216	20030402
US 2003220255	A1 Provisional	US 2002-375255P	20020423
		US 2003-406426	20030403

PRIORITY APPLN. INFO: US 2002-375255P 20020423; DK  
2002-499 20020404; US  
2003-406426 20030403

AN 2004-022543 [02] WPIDS  
AB WO2003084563 A UPAB: 20040107

NOVELTY - In the treatment or prevention of an early cardiac or early  
cardiovascular disease in a diabetic or non-diabetic patient a glucagon  
like peptide-1 (GLP1) agonist or its salt is used.

ACTIVITY - Cardiant; Cardiovascular-Gen.; Antiarrhythmic; Antianginal; Antiarteriosclerotic; Vasotropic; Hypotensive.

MECHANISM OF ACTION - Glucose metabolism regulator; Cardiovascular hemodynamics regulator; Brain natriuretic peptide (BNP) in plasma and/or heart tissue inhibitor. Hearts from 12 streptozotocin (STZ)-treated pigs were collected. The pigs were treated with STZ 2 weeks prior to dosing with either the GLP-1 derivative, Arg34, Lys26(N- eta ( gamma -Glu(N- alpha -hexadecanoyl))) -GLP-1(7-37) (NN2211) for 4 weeks, at a dose of 3.3 micro g/kg, subcutaneously once daily or with a vehicle. STZ-treated pigs were either hyperglycemic or glucose intolerant and had impaired insulin secretion upon oral glucose tolerance tests. BNP mRNA and protein levels in cardiac biopsies were measured with real-time PCR and RIA assays, respectively. BNP mRNA levels were normalized by beta -actin mRNA levels. BNP mRNA levels were similar in right atrial (RA), left atrial (LA) and in left ventricular (LV) biopsies from vehicle treated diabetic pigs (-GLP). However, in hearts from NN2211 (+GLP) treated pigs the levels of BNP were significantly lower than in vehicle treated pigs. The BNP mRNAs (arb.units) in the RA, LA and LV in the NN2211/vehicle treated pigs was found to be 0.13/1.3, 0.37/1.5 and 0.75/1.15, respectively.

USE - For the treatment or prevention of an early cardiac or early cardiovascular disease (e.g. left ventricular hypertrophy, coronary artery disease, essential hypertension, acute hypertensive emergency, cardiomyopathy, heart insufficiency, exercise tolerance, chronic heart failure, arrhythmia, cardiac dysrhythmia, syncope, atherosclerosis, mild chronic heart failure, angina pectoris, cardiac bypass reocclusion, intermittent claudication (e.g. atherosclerosis obliterans), diastolic dysfunction and systolic dysfunction) in a diabetic or non-diabetic patient; for the preparation of a pharmaceutical composition for reducing the level of brain natriuretic peptide (BNP) in plasma and/or heart tissue in a diabetic or non-diabetic patient (all claimed). Also useful for the treatment of myocardial infarction, acute coronary syndrome, unstable angina, non-Q-wave cardiac necrosis, Q-wave myocardial infarct and morbidity after stroke.

ADVANTAGE - The GLP-1 agonists are in the form of stable derivatives and exhibit a protracted profile of action compared to the corresponding other GLP-1 analogs. The GLP-1 analogs lower the brain natriuretic peptide (BNP) in the plasma and/or heart tissue, in addition to lowering blood glucose and plasma lipids.

Dwg.0/1

L69 ANSWER 7 OF 8 WPIDS COPYRIGHT 2004 THOMSON DERWENT on STN

ACCESSION NUMBER: 2000-514584 [46] WPIDS  
CROSS REFERENCE: 2000-490999 [43]; 2001-514422 [56]; 2004-042706 [04]  
DOC. NO. CPI: C2000-153464  
TITLE: New formulations comprising an exendin or exendin agonist peptide used for increasing the sensitivity of a subject to insulin totreat diabetes.  
DERWENT CLASS: A96 B04  
INVENTOR(S): KOLTERMAN, O; LITALIEN, J J; YOUNG, A; L'ITALIEN, J J;  
KOLTERMAN, O G; YOUNG, A A  
PATENT ASSIGNEE(S): (AMYL-N) AMYLIN PHARM INC; (KOLT-I) KOLTERMAN O G;  
(YOUN-I) YOUNG A A  
COUNTRY COUNT: 91  
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 2000041546	A2	20000720	(200046)*	EN	281
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL					
OA PT SD SE SL SZ TZ UG ZW					
W: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES					
FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS					
LT LU LV MA MD MG MK MN MX NO NZ PL PT RO RU SD SE SG SI SK SL					
TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW					
AU 2000035819	A	20000801	(200054)		
NO 2001003468	A	20010914	(200163)		



EP 1140145 A2 20011010 (200167) EN  
 R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT  
 RO SE SI  
 BR 2000007820 A 20011120 (200202)  
 JP 2002534450 W 20021015 (200282) 211  
 CN 1384755 A 20021211 (200324)  
 US 2003087820 A1 20030508 (200337)

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2000041546	A2	WO 2000-US902	20000114
AU 2000035819	A	AU 2000-35819	20000114
NO 2001003468	A	WO 2000-US902	20000114
		NO 2001-3468	20010712
EP 1140145	A2	EP 2000-914425	20000114
		WO 2000-US902	20000114
BR 2000007820	A	BR 2000-7820	20000114
		WO 2000-US902	20000114
JP 2002534450	W	JP 2000-593167	20000114
		WO 2000-US902	20000114
CN 1384755	A	CN 2000-804847	20000114
US 2003087820	A1 Provisional	US 1999-116380P	19990114
	Provisional	US 2000-175365P	20000110
	CIP of	WO 2000-US902	20000114
	CIP of	US 2001-889330	20011227
		US 2002-157224	20020528

FILING DETAILS:

PATENT NO	KIND	PATENT NO
AU 2000035819	A Based on	WO 2000041546
EP 1140145	A2 Based on	WO 2000041546
BR 2000007820	A Based on	WO 2000041546
JP 2002534450	W Based on	WO 2000041546

PRIORITY APPLN. INFO: US 2000-175365P 20000110; US  
 1999-116380P 19990114; US  
 2001-889330 20011227; US  
 2002-157224 20020528

AN 2000-514584 [46] WPIDS  
 CR 2000-490999 [43]; 2001-514422 [56]; 2004-042706 [04]  
 AB WO 200041546 A UPAB: 20040115

NOVELTY - New formulation (I) comprising an exendin or exendin agonist peptide, a **buffer** and an iso-osmolality modifier has a pH of 3-7.

DETAILED DESCRIPTION - An INDEPENDENT CLAIM is also included for a solid or dry powder formulation (II) comprising 1-100% (w/w) of an exendin or exendin agonist peptide and for less than 100% exendin, a bulking agent.

ACTIVITY - Antidiabetic.

Fourteen subjects with type 2 diabetes were treated with diet and oral hypoglycemic agents and studied following withdrawal of oral agents for 10-14 days. Assessments were made following randomized, subcutaneous injection of placebo, 0.01, 0.02, 0.05 and 0.1 micro g/kg exendin-4 on separate days following an overnight fast. Injections were given immediately before a standardized Sustacal(RTM) meal 97kcal/kg) followed by collection of plasma glucose samples at frequent intervals during the subsequent 300 minutes. The glycemic response was measured as the time-weighted mean change in plasma concentration during the 5 hour period. The response ranged from a +42.0 plus or minus 7.9 mg/dl increment above the fasting glucose concentration for placebo compared a 30.5 plus or minus 8.6 mg/dl decrement below the fasting glucose concentration with 0.1 micro g/kg exendin-4.

MECHANISM OF ACTION - None given.

USE - The exendin or exendin agonist is used to increase the sensitivity of a subject to insulin (claimed) to treat diabetes and disorders which would benefit from agents which lower plasma glucose levels and disorders which would benefit from agents that delay and/or slow gastric emptying or reducing food intake.

Dwg.0/18

L69 ANSWER 8 OF 8 WPIDS COPYRIGHT 2004 THOMSON DERWENT on STN

ACCESSION NUMBER: 1999-540562 [45] WPIDS  
CROSS REFERENCE: 1998-207039 [18]; 1998-239721 [21]; 1999-540500 [45];  
1999-540507 [45]; 1999-540561 [45]; 1999-550859 [46];  
1999-561858 [47]; 2000-072123 [06]; 2001-595691 [67];  
2003-852812 [79]  
DOC. NO. CPI: C1999-157857  
TITLE: New derivatives of glucagon-like peptide-1 and exendin  
containing lipophilic substituent, for treating diabetes  
and obesity.  
DERWENT CLASS: B04 B05 D16  
INVENTOR(S): HUUSFELDT, P O; KNUDSEN, L B; MADSEN, K; NIELSEN, P F;  
BJORN, S E; KAARSHOLM, N C; OLSEN, H B; PEDERSEN, F Z  
PATENT ASSIGNEE(S): (NOVO) NOVO-NORDISK AS; (NOVO) NOVO NORDISK AS; (HUUS-I)  
HUUSFELDT P O; (KNUD-I) KNUDSEN L B; (MADS-I) MADSEN K;  
(NIEL-I) NIELSEN P F  
COUNTRY COUNT: 86  
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 9943708	A1	19990902	(199945)*	EN	69
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL					
OA PT SD SE SL SZ UG ZW					
W: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD					
GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV					
MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT					
UA UG US UZ VN YU ZW					
ZA 9901571	A	19991124	(200001)		64
AU 9932477	A	19990915	(200004)		
EP 1056775	A1	20001206	(200064)	EN	
R: AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU NL PT SE					
US 6268343	B1	20010731	(200146)		
US 2001047084	A1	20011129	(200202)		
JP 2003522099	W	20030722	(200350)		91

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE	
WO 9943708	A1	WO 1999-DK86	19990225	
ZA 9901571	A	ZA 1999-1571	19990226	
AU 9932477	A	AU 1999-32477	19990225	
EP 1056775	A1	EP 1999-936077	19990225	
		WO 1999-DK86	19990225	
US 6268343	B1	Provisional	US 1997-35904P	19970124
		Provisional	US 1997-36255P	19970124
		Provisional	US 1997-36226P	19970125
		CIP of	WO 1997-DK340	19970822
		CIP of	US 1997-918810	19970826
		CIP of	US 1998-38432	19980311
		Provisional	US 1998-82478P	19980421
		Provisional	US 1998-82480P	19980421
		Provisional	US 1998-82802P	19980423
		Provisional	US 1998-84357P	19980505
			US 1999-258750	19990226
US 2001047084	A1	Provisional	US 1998-84357P	19980505
		Cont of	WO 1999-DK86	19990224

	Cont of	US 1999-312177	19990514
		US 2001-886311	20010621
JP 2003522099	W	WO 1999-DK86	19990225
		JP 2000-533458	19990225

FILING DETAILS:

PATENT NO	KIND	PATENT NO
AU 9932477	A Based on	WO 9943708
EP 1056775	A1 Based on	WO 9943708
US 6268343	B1	WO 9808871
		WO 9943341
		WO 9943707
		WO 9943708
JP 2003522099	W Based on	WO 9943708

PRIORITY APPLN. INFO: US 1998-84357P 19980505; DK  
 1998-274 19980227; DK  
 1996-931 19960830; DK  
 1996-1259 19961108; DK  
 1996-1470 19961220; DK  
 1998-263 19980227; DK  
 1998-264 19980227; DK  
 1998-268 19980227; DK  
 1998-272 19980227; DK  
 1998-508 19980408; DK  
 1998-509 19980408

AN 1999-540562 [45] WPIDS  
 CR 1998-207039 [18]; 1998-239721 [21]; 1999-540500 [45]; 1999-540507 [45];  
 1999-540561 [45]; 1999-550859 [46]; 1999-561858 [47]; 2000-072123 [06];  
 2001-595691 [67]; 2003-852812 [79]

AB WO 9943708 A UPAB: 20031208

NOVELTY - Derivatives (A1) of GLP-1 (glucagon-like peptide-1) are new.

DETAILED DESCRIPTION - Derivatives (A1) of GLP-1 (glucagon-like peptide-1) (7-c) (with c = 35 or 36) having just one lipophilic substituent (LS) attached to the C-terminal amino acid (aa) and derivatives (A2) of exendin with LS attached to at least one aa of the parent peptide. A1 excludes compounds Arg26, Arg34, Lys36-(N epsilon (omega -carboxyX)-GLP-1(7-36)-OH

X = nonadecanoyl, heptadecanoyl, undecanoyl or heptanoyl.

An INDEPENDENT CLAIM is also included for compositions containing A1 and A2 plus a vehicle or carrier.

ACTIVITY - Antidiabetic; anti-obesity; insulinotropic; hypoglycemic.

MECHANISM OF ACTION - A1 stimulate secretion of insulin but suppress that of glucagon. They also inhibit gastric emptying and pancreatic secretion and may reduce food intake.

USE - A1 and A2 are used to treat (non-)insulin-dependent diabetes mellitus and obesity, and also to prevent hyperglycemia.

ADVANTAGE - A1 and A2 have a greater persistence in vivo than corresponding peptides without LS (because of reduced sensitivity to dipeptidyl peptidases). When formulated with other antidiabetic agents, they often produce a synergistic effect.

Dwg.0/0

=>